Recent efforts to enhance clinical trial participation have garnered attention, prompting discussions about accessibility and the systemic challenges faced by patients. The Department of Health and Human Services announced a new initiative in June aimed at streamlining clinical research in the United States, including a public request for information to potentially modify federal regulations that currently disincentivize trial sponsors from covering participant expenses, such as travel and lodging. These ongoing efforts highlight the pressing need to improve the landscape for patients seeking trial participation, reports BritPanorama.
Despite a high level of interest among patients, particularly those with chronic diseases, many face significant hurdles in finding appropriate trials. A recent survey indicated that 71% of patients expressed willingness to participate if given the opportunity, yet two-thirds reported that their healthcare providers had not discussed clinical trials with them. Moreover, a study from 2020 noted that only 9% of adults had ever been invited to participate in a clinical trial.
The recruitment of participants is only the first challenge; retention remains a critical issue, according to Alan Balch, executive board chair at the Patient Advocate Foundation. He noted that every interaction with participants can present barriers related to access and affordability. Balch emphasized that both recruitment and retention must be addressed to ensure that clinical trials can succeed.
To bridge the knowledge gap, nearly 200 patient advocacy and public health groups sent a letter to U.S. Senate sponsors of the Clinical Trial Modernization Act in July. This bill proposes measures that would allow trial sponsors to cover various costs incurred by participants, including insurance deductibles and out-of-pocket expenses related to participation. It also aims to exempt financial support for clinical trial participation from federal taxation, which could alleviate concerns about losing Medicaid eligibility.
Why participate in clinical trials?
Clinical trials are a vital component of medical research, providing opportunities to test new treatments and evaluate their efficacy. Participants may be offered experimental therapies while others receive placebos, and these trials can be crucial for individuals with serious health conditions. Mark Fleury from the American Cancer Society noted that for many patients, such trials represent the best chance to extend their lives or enhance their quality of life.
Jim Taylor, an advocate for Alzheimer’s research, shared his personal experience in participating in observational trials, aiming to provide insights into what participating entails. He underscores that participating in clinical trials helps advance scientific knowledge, potentially benefiting future patients.
Finding a clinical trial
Efforts to identify suitable clinical trials often leave patients and their healthcare providers at a disadvantage. A survey revealed that, although a significant majority of primary care physicians express a willingness to reference patients to trials, only a minority have actually done so. Communication around clinical trials mostly occurs when patients proactively inquire due to lack of response to standard treatments or progression of their conditions.
Despite growing interest, many patients lack direction on how to locate relevant trials. Organizations like the American Cancer Society and various disease-specific foundations offer resources and clinical trial matching services to assist patients in identifying suitable opportunities.
The logistics of trial participation represent another challenge. Clinical trials predominantly take place at urban academic medical centres, meaning patients living outside these areas often encounter barriers to access. Fleury pointed out that a significant proportion of patients do not participate in trials simply because no appropriate options exist nearby.
There’s a trial, but you can’t enroll or afford it
Even when a trial is available, other obstacles may prevent patient enrollment. Many trials require regular attendance, assessments, and compliance with various protocols, which can be difficult for patients to manage. A 2019 study highlighted that over half of cancer patients surveyed could not participate due to a lack of trials tailored to their specific cancer type and stage.
Financial considerations also play a substantial role in determining if a patient can participate. While trial sponsors typically cover the costs directly related to the trial itself, participants may still face significant incidental expenses, including travel and lodging. Under the Affordable Care Act, some routine patient costs are covered, but deductibles and out-of-network charges can hinder access further.
As the push for clinical trial reform continues, advocates like Wendy Selig emphasize the necessity for transparency in trial sponsorship regarding incidental costs. Selig indicates that patients should proactively inquire about available financial support to alleviate some of the burden associated with participation.
In this evolving landscape, the conversation surrounding clinical trial participation underscores an ongoing need for improvement and accessibility. With systemic changes on the horizon, there is cautious hope for a more inclusive approach to clinical research that could benefit diverse patient groups.
